TIDMAPH

RNS Number : 4669X

Alliance Pharma PLC

10 August 2018

 
 For immediate release   10 August 2018

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 31 July 2018 the Company's issued share capital consists of 515,127,294 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 515,127,294 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

 
Alliance Pharma plc 
 Peter Butterfield, Chief Executive Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk                        + 44 (0) 1249 466966 
Buchanan                                             + 44 (0) 20 7466 
 Mark Court / Sophie Wills / Gemma Mostyn-Owen                   5000 
Numis Securities Limited 
 Nominated Adviser: Michael Meade / Freddie 
 Barnfield                                           + 44 (0) 20 7260 
 Corporate Broking: James Black / Toby Adcock                    1000 
Investec Bank plc 
 Corporate Finance: Daniel Adams / Ed Thomas          +44 (0) 20 7597 
 Corporate Broking: Patrick Robb / Rob Baker                     5970

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRGGURCRUPRURU

(END) Dow Jones Newswires

August 10, 2018 05:00 ET (09:00 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Alliance Pharma Charts.